CD19 and rheumatoid arthritis: To test the latter possibility, PB CD19+ cells from ACPA+ RA patients (n=5) were transfected with miR-155 or control inhibitor and stimulated with anti-IgM, CD40L, IL-21 and BAFF or left unstimulated for 7 days.